SNS-032. Cyclin-dependent kinase inhibitor, oncolytic

Drugs of the Future

Volumn 33, Issue 11, 2008, Pages 932-937

  Vasiliou, S ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLOOXYGENASE 2; FLAVOPIRIDOL; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PROSTAGLANDIN E2; VASCULOTROPIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADVANCED CANCER; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BREAST CARCINOMA; CELL CYCLE ARREST; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON CARCINOMA; CONSTIPATION; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; GASTRIC ULCER BLEEDING; GLIOBLASTOMA; HEART VENTRICLE EXTRASYSTOLE; HUMAN; IC 50; LEUKEMIA; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; OVARY CARCINOMA; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; SOLID TUMOR; VOMITING;

EID: 60549103885     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.011.1281261     Document Type: Article

References (39)

1. Xiao, H.-Y., Misra, R.N. (Bristol-Myers Squibb Co.). N-[5- [5-Alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases. CA 2394552, EP1240166, JP 2003516987, WO 2001044242.
2. Xiao, H.-Y., Misra, R.N. (Bristol-Myers Squibb Co.). N-[5- [5-Alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases. CA 2417254, EP 1303513, JP 2004509857, WO 2002010162.
3. Kim, K.S., Kimball, D., Cai, Z.-W. et al. (Bristol-Myers Squibb Co.). Aminothiazole inhibitors of cyclin dependent kinases. US 6262096.
4. Misra, N.R., Xiao, H., Kim, K.S. et al. N-(Cycloalkylamino)acyl-2- aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5- [5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl] -4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 2004, 47(7): 1719-28.
5. Malumbres, M., Pevarello, P., Barbacid, M., Bischoff, J.R. CDK inhibitors in cancer therapy: What is next? Trends Pharmacol Sci 2008, 29(1): 16-21.
6. Murray, A.W., Marks, D. Can sequencing shed light on cell cycling? Nature 2001, 409(6822): 844-6.
7. Kapasi, A.J., Spector, D.H. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome. J Virol 2008, 82(1): 394-407.
8. Fisher, R.P. Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci 2005, 118(Pt. 22): 5171-80.
9. Schang, L.M. Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication. Biochim Biophys Acta 2004, 1697(1-2): 197-209.
10. Monaco, E.A., Vallano, M.L. Role of protein kinases in neurodegenerative disease: Cyclin-dependent kinases in Alzheimer's disease. Front Biosci 2005, 10: 143-59.
11. Malumbres, M., Barbacid, M. To cycle or not to cycle: A critical decision in cancer. Nat Rev Cancer 2001, 1(3): 222-32.
12. Misra, R.N., Xiao, H.-Y., Kim, K.S. et al. BMS-387032: A selective CDK2 inhibitor with potent anti-tumor activity. 225th ACS Natl Meet (March 23-27, New Orleans) 2003, Abst MEDI 18.
13. Nuwayhid, S.J., Hyde, J., Aleshin, A., Walker, D.H., Arkin, M.R. SNS-032 is a potent and selective inhibitor of CDK2, 7 and 9 and induces cell death by inhibiting cell cycle progression and the expression of antiapoptotic proteins. Proc Am Assoc Cancer Res (AACR) 2007, 47: Abst 2079.
14. Macor, P., Secco, E., Zorzet, S., Tripodo, C., Celeghini, C., Tedesco, F. An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. Curr Pharm Des 2008, 14(21): 2023-39.
15. Mukhopadhyay, P., Ali, M.A., Nandi, A., Carreon, P., Choy, H., Saha, D. The cyclin dependent kinase 2 inhibitor downregulates interleukin 1-beta mediated induction of cyclooxygenase 2 expression in human lung carcinoma cells. Cancer Res 2006, 66(3): 1758-66.
16. Ali, M.A., Choy, H., Habib, A.A., Saha, D. SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia 2007, 9(5): 370-81.
17. Lane, M.E., Temple, K., Yu, B., Nguyen, H., Wadler, S. Combined treatment with cisplatin and a novel cdk2 specific inhibitor (BMS 387032), results in cytotoxic synergy in human colon carcinoma cells that is dependent on dose, sequence and cychin D1 expression. Proc Am Assoc Cancer Res (AACR) 2003, 44(2nd Ed.): Abst 706.
18. Kodym, E., Kodym, R., Reis, A., Story, M., Saha, D. SNS-032 enhances cellular radiosensitivity in hypoxic and quiescent non-small cell lung cancer cells. Proc Am Assoc Cancer Res 2008, 49: Abst 416.
19. Lee, F.Y.F., Camuso, A., Clark, J. et al. BMS-387032, a selective inhibitor of cyclin-dependent kinase 2 with potent anti-tumor activity in vivo. Proc Am Assoc Cancer Res (AACR) 2003, 44(2nd Ed): Abst 958.
20. Kamath, A.V., Chong, S., Chang, M., Marathe, P.H. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats. Cancer Chemother Pharmacol 2005, 55(2): 110-6.
21. Heath, E.I., Bible, K., Martell, R.E., Adelman, D.C., Lorusso, P.M. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 2008, 26(1): 59-65.
22. Jones, S.F., Burris, H.A., Kies, M. et al. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 given intravenously every three weeks in patients with metastatic refractory solid tumors. Proc Am Soc Clin Oncol (ASCO) 2003, 22: Abst 798.
23. Shapiro, G., Lewis, N., Bai, S. et al. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 with a 24-hr infusion given every three weeks in patients with metastatic refractory solid tumors. Proc Am Soc Clin Incol (ASCO) 2003, 22: Abst 799.
24. Study of intravenously administered SNS-032 in patients with advanced B-lymphoid malignancies (NCT00446342). ClinicalTrials.gov Web site, November 20, 2008.
25. Goldberg, Z., Wierda, W., Chen, R. et al. A phase 1 trial of SNS-032, a potent and specific CDK 2, 7 and 9 inhibitor, in chronic lymphocytic leukemia and multiple myeloma. Haematologica [13th Congr Eur Hematol Assoc (EHA) (June 12-15, Copenhagen) 2008] 2008, 93(Suppl. 1): Abst 0792.
26. Safety assessment of one-hour infusions of SNS-032 for the treatment of select advanced solid tumors (NCT00292864). ClinicalTrials.gov Web site, November 20, 2008.
27. Ma, Y., Cress, W.D. Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity. Oncogene 2007, 26(24): 3532-40.
28. Reddy, M., Arbitrario, J., Jones, J., Silverman, J., Howlett, A., Taverna, P. SNS-032 has potent antitumor activity in vivo against human leukemia and multiple myeloma xenografts. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Oct 22-26, San Francisco) 2007, Abst A258.
29. Wong, T.W., Wang, C., Lee, F. et al. Identification of a biomarker of CDK2 inhibition with BMS-387032. 15th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst C84.
30. McCormick, J., Gadgeel, S.M., Helmke, W. et al. Phase I study of BMS-387032, a cyclin dependent kinase (CDK) 2 inhibitor. Proc Am Soc Clin Oncol (ASCO) 2003, 22: Abst 835.
31. Hawtin, R., Cohen, R., Haas, N. et al. SNS-032 exhibits dose-dependent mechanism-based inhibition of CDK7 and CDK9 in peripheral blood mononuclear cells from patients with advanced cancers treated in an ongoing phase 1 trial. 12th Congr Eur Hematol Assoc (EHA) (June 7-10, Vienna) 2007, Abst 0742.
32. Walton, M.I. Studies of the molecular pharmacology of the CDK2 inhibitor BMS-387032 in human tumour cell lines. 15th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst C89.
33. Conroy, A., Stockett, D.E., Nuwayhid, S., Arkin, M.R., Hawtin, R.E. SNS-032 is a potent and selective CDK2, 7 and 9 inhibitor that drives apoptosis in the multiple myeloma cell line RPMI-8226. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 1815.
34. Mukhopadhyay, P., Ali, M.A., Carreon, P., Nandi, A., Saha, D. The cyclin dependent kinase 2 inhibitor downregulates interleukin 1-beta mediated induction of cyclooxygenase 2 expression in human lung carcinoma cells. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 4917.
35. Wong, T.W., Kimball, D., Misra, R.N. et al. BMS-387032, a potent and selective inhibitor of cyclin-dependent kinase 2 (CDK2) induces cell cycle arrest and apoptosis in human tumor cells. Proc Am Assoc Cancer Res (AACR) 2003, 44(2nd Ed): Abst 3125.
36. Chen, R., Chubb, S., Hoch, U., Hawtin, R., Fox, J., Gandhi, V., Plunkett, W. SNS-032, a novel inhibitor of cyclin-dependent kinases 2, 7 and 9, blocks transcription of cyclin D1 and Mcl-1, causing cell death in mantle cell lymphoma cell lines. Proc Am Assoc Cancer Res (AACR) 2008, 49: Abst 756.
37. Ali, M., Ding, L.-H., Story, M., Habib, A., Saha, D. Cyclin dependent kinase inhibitor (SNS-032) prevents hypoxia mediated glioblastoma cell invasion by inhibiting the expression of HIF-1alpha. Proc Am Assoc Cancer Res (AACR) 2008, 49: Abst 2040.
38. Ma, Y., Cress, D. Regulation of p57 (Kip2) by the cyclin depenent kinase inhibitor BMS-387032/SNS-032 is dependent on E2F1. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 453.
39. Chen, R., Wierda, W.G., Benaissa, S. et al. Mechanism of action of SNS-032, a novel cyclin dependent kinase inhibitor, in chronic lymphocyte leukemia: Comparison with flavopiridol. Blood [49th Annu Meet Am Soc Hematol (Dec 8-11, Atlanta) 2007] 2007, 110(11): Abst 3112.